Analytics pros more than just 'quants,' says study

Market research departments of a number of life science companies incorporate analytics functions, either partially or fully, a study shows. These functions run the gamut from forecasting and sales force analytics to competitive intelligence and market sizing, along with eight others.

While analytics pros are vital, they're a misunderstood lot.

“People think of analytics as just number crunching. There's so much qualitative involved,” said Rob Naylor, senior analyst at Best Practices, LLC, which ran the study to identify models around which companies can build and maximize the business value of market analytics.  

One way involves staffing. The number of full-time employees required varied among the 21 firms. Proper staffing levels depend on several variables including product lifecycle. A well-established blockbuster may require one full-timer, while a Phase III candidate, three.

Another useful tactic: positioning. At one company, all 12 analytics functions were housed in one department. At another, the 12 were divided among seven. While each style has its advantages, in general, “It's good to integrate as many functions as you can to eliminate duplication,” said Haswell.
Bottom line: analytics has to be a core competency, with market conditions and pipelines determining to what degree this function grows.

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.